The Evolving Treatment Landscape of Small Cell Lung Cancer - Episode 7

IMpower 133 Trial and Patient Selection for Durvalumab + Chemotherapy vs Atezolizumab + Chemotherapy

July 18, 2022

Charu Aggarwal, MD, MPH, Taofeek K. Owonikoko, MD, PhD, Charles M. Rudin, MD, PhD, Vivek Subbiah, MD, Jared Weiss, MD

Dr Charu Aggarwal shares data from the IMpower133 trial of atezolizumab plus chemotherapy for SCLC, and how to select the appropriate frontline therapy.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Overview of SCLC and Importance of Early Diagnosis

EP. 2: Use of the TNM Staging System in SCLC

EP. 3: Progress in the Treatment and Management of SCLC

EP. 4: Patient Profile 1: A 68-Year-Old Male with SCLC and Brain Metastases

EP. 5: Frontline Therapy for SCLC: The CASPIAN Trial of Durvalumab + Chemotherapy

EP. 6: Management of Adverse Events Associated with Durvalumab + Chemotherapy

Now Viewing

EP. 7: IMpower 133 Trial and Patient Selection for Durvalumab + Chemotherapy vs Atezolizumab + Chemotherapy

EP. 8: Ongoing Trials and Real-World Studies in Frontline SCLC

EP. 9: Patient Profile 2: A 60-Year-Old Man with SCLC Progressing on First-Line Therapy

EP. 10: Second Line Treatment Options in SCLC and Selecting the Appropriate Therapy

EP. 11: Lurbinectedin for SCLC Treatment in the Second-Line Setting

EP. 12: Patient Profile 3: A 70-Year-Old Man with SCLC Receiving Chemotherapy in the Second-Line Setting

EP. 13: Choosing the Appropriate Treatment in the Second Line Setting in SCLC

EP. 14: Investigational Agents in SCLC in the Second Line Setting and Beyond

EP. 15: Clinical Practice Pearls and the Future of SCLC